ALK and non-small cell lung carcinoma: With a favorable progression‐free survival (PFS) of 34.8 months with alectinib versus 10.9 months with crizotinib in untreated patients [4], alectinib has been approved and recommended as a first‐line regimen for ALK‐positive metastatic NSCLC.